Browsing: Weight Loss

Your gym sessions may be locked-in, and your nutrition might be on-point, but if you are failing to hit the hay at a reasonable time, you could be stalling your progress toward getting slimmer. While we are constantly told that adequate sleep is a necessary part of the weight loss journey, getting to bed on…

Eli LillyLLYfell 0.35% in premarket after reporting positive results from two further Phase 3 trials of retatrutide and confirming it will submit a biologics license application to the FDA in the first quarter of 2027. The drug targets three metabolic hormones, GLP-1, GIP and glucagon, against two for Lilly’s current Zepbound and one for Novo…

Eli LillyLLY is a dominant player in the cardiometabolic market, backed by a strong and expanding GLP-1 portfolio. Its GLP-1 lineup includes Mounjaro and Zepbound (tirzepatide injections) for type II diabetes (T2D) and obesity, respectively, and the newly approved oral obesity therapy, Foundayo (orforglipron)

It’s been about a year since Patrick Gilligan took the helm of Point32Health, the state’s second-largest health insurer and parent company of Harvard Pilgrim Health Care and Tufts Health Plan

Eli Lilly’s Retatrutide met primary endpoints in two Phase III trials, delivering up to 22.6% body weight loss in adults with severe obesity and cardiovascular disease

You have probably heard the buzz about using pomegranate peel for weight loss. It sounds like a simple, natural hack, doesn’t it? But before you start brewing your own tea or hunting for supplements, it is worth looking at what the science actually says. When it comes to pomegranate peel benefits, the reality is a…

This is a paid press release. Contact the press release distributor directly with any inquiries.

The race to treat obesity and diabetes is shifting again after Eli Lilly pushed back approval plans for its next-generation obesity drug, retatrutide, to Q1 2027, even as phase 3 data showed weight loss of up to 22.6% and blood sugar benefits. This mix of regulatory delay and clinical progress can reshape expectations for companies…

Glucagon-like peptide-1 (GLP-1) receptor agonists, mainly used to treat type 2 diabetes and obesity, are associated with a significantly higher risk of hair loss than other diabetes medications, according to a new study published inThe BMJ

A study of 50,000 people found a link between GLP-1 agonists and alopecia. Regulators in the US and UK have received hundreds of reports of hair loss